Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
What is the 'cicada' COVID variant?
April 6, 2026
A formerly rare strain of COVID, BA.3.2, now is showing up in Ohio and 24 other states. Experts say so far it hasn't caused illness any more severe than other strains, but it might be somewhat more resistant to vaccines, as 91.7 WVXU News recently reported. Scientists have nicknamed the variant "cicada" due to its former low profile and current resurgence.
UC opens zebrafish research facility to study infertility
April 6, 2026
The University of Cincinnati is launching a state-of-the-art zebrafish research facility that scientists say could help explain how environmental toxins affect fertility, as WKRC-TV/Local 12 and WLWT-TV/Ch. 5 recently reported.
UC launches new Center for Public Health
April 6, 2026
The University of Cincinnati College of Medicine recently announced Suzanne Judd, PhD, as the inaugural director of its new Center for Public Health. The hire follows a national search launched in August 2025, as the Cincinnati Business Courier reported.